Srg3, a mouse homolog of BAF155, is a novel p53 target and acts as a tumor suppressor by modulating p21(WAF1/CIP1) expression

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The SWI/SNF chromatin remodeling complex plays a role in cancer, with some subunits acting as tumor suppressors.
• The precise mechanisms by which SWI/SNF subunits exert tumor suppression are not fully understood.

Purpose of the Study:

• To investigate the in vivo function of Srg3, a mouse homolog of BAF155 and a core SWI/SNF subunit, in tumor suppression.
• To elucidate the molecular pathways involving Srg3, p53, and p21 in response to DNA damage and tumorigenesis.

Main Methods:

• Utilized mouse models with Srg3 deficiency and p53 haploinsufficiency.
• Analyzed Srg3 degradation in response to DNA damage induced by p53.
• Assessed cell-cycle progression and apoptotic responses to DNA damage.
• Examined tumor formation, specifically sarcomas, in genetically modified mice.

Main Results:

• Srg3 functions as a tumor suppressor in vivo, inhibiting tumorigenesis.
• DNA damage signals induce p53-mediated degradation of Srg3.
• Srg3 deficiency promotes G1 cell-cycle arrest but antagonizes apoptosis by upregulating p53 and p21.
• Srg3 heterozygous mice developed sarcomas, with tumor development accelerated by p53 haploinsufficiency.
• Tumors exhibited high p53 and p21 expression but lacked Srg3.

Conclusions:

• Srg3 has a novel role in tumor suppression through its regulation of DNA damage responses.
• The interplay between Srg3, p53, and p21 is critical for maintaining genomic integrity and preventing sarcoma formation.
• These findings offer new insights into the genetic pathways governing SWI/SNF complex-mediated tumor suppression.